I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Roche and Genentech at

ACTRIMS Forum 2025

February 27 - March 01

Florida, USA

actrims.org

We will be contributing to topics related to

Neuroscience

Agenda

Medical Materials

11:00 PM

Duration 45mins Florida, USA

Exploring the Conceptual Relevance of 9HPT and T25FW Through Perspectives from People with MS

Clinch, Susanne; Miller, Deborah; Bonati, Ulrike; Craveiro, Licinio; Twiss, James

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

Subcutaneous Ocrelizumab: Exploratory Pharmacokinetic, Pharmacodynamic, and Serum Neurofilament Light Chain Analysis in Patients with Multiple Sclerosis Across Body Weight and MRI Activity Levels

Bermel, Robert; Pearson, Owen R.; Villar, Luisa M.; Centonze, Diego; Shen, Yun-An; Kletzl, Heidemarie; Acosta, Juan; Figueiredo, Catarina; Townsend, Ben; Giacobino, Caroline; Newsome, Scott D.

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

Exposure-Response Analyses of Ocrelizumab in Patients With Relapsing Multiple Sclerosis in OPERA I and II Over 10 Years

Bermel, Robert; Giovannoni, Gavin; Ladeira, Filipa; Repovic, Pavle; Tur, Carmen; Cutter, Gary; Clayton, David; Lindau, Nicolas; Schneble, Hans-Martin; Chognot, Cathy; Wang, Qing; Craveiro, Licinio; Hauser, Stephen L.

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

Fenebrutinib Maintains Low Disease Activity in Relapsing Multiple Sclerosis: Clinical, Safety and Biomarker Results From the FENopta Open-Label Extension

Bar-Or, Amit; Oh, Jiwon; Dufek, Michal; Budincevic, Hrvoje; Habek, Mario; Caunt, Maresa; Harp, Christopher; Sierzega, Malgorzata; Clayton, David; Chen, Ying-Fang; Ratchford, John N.; Goodyear, Alexandra; Drulovic, Jelena

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

Imaging and Fluid Biomarkers of Disability Progression During 2 Years of Ocrelizumab Treatment in Black and African American and Hispanic and Latino People With Multiple Sclerosis in CHIMES

Amezcua, Lilyana; Monson, Nancy L.; Williams, Mitzi J.; Reder, Anthony T.; Wu, Gregory F.; Vartanian, Timothy; Pei, Jinglan; Harp, Christopher; Clayton, David; Abioye, Ibraheem; Bernitsas, Evanthia

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

How Does Fenebrutinib Work? Examining Kinetic and Mechanistic Features That Influence BTK Potency, Selectivity and Pharmacology

Johnson, Adam; Wittwer, Arthur; Pufahl, Robert; Durk, Matthew; Goodyear, Alexandra; Giovannoni, Gavin

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

Infant B-cell levels, ocrelizumab placental transfer and maternal humoral immunity pregnancy: Primary analysis of the prospective multicentre, open-label Phase IV MINORE study

Hellwig, Kerstin; Bove, Riley; Oreja-Guevara, Celia; Dobson, Ruth; Maillart, Elisabeth; Jacobs, Dina; McElrath, Thomas F.; Derfuss, Tobias; Pietrasanta, Carlo; Kletzl, Heidemarie; Kazlauskaite, Agne; Zecevic, Dusanka; Raposo, Catarina; Craveiro, Licinio; Lin, Chien-Ju; Pasquarelli, Noemi; Vukusic, Sandra

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

Deriving an NfL Threshold Equivalent From Atellica® to Simoa® Assays in Ocrelizumab Phase 3 Trials to Assess Disease Activity Risk in RMS

Bar-Or, Amit; Jia, Sherman; Thanei, Gian-Andrea; Herman, Ann; Winger, Ryan; Bakdache, Fabien; Krumova, Petranka; Raposo, Catarina; Harp, Chris; Benkert, Pascal; Kuhle, Jens

Neuroscience | Multiple Sclerosis

11:45 PM

Duration 45mins Florida, USA

Non Serious and Recurrent Infections in Patients With Multiple Sclerosis Treated With Ocrelizumab: Long-Term Analysis of 13 Pooled Interventional Clinical Trials

Bermel, Robert; Buttman, Mathias; Conte, Antonella; Tallantyre, Emma; Lebrun-Frenay, Christine; Chognot, Cathy; Pasquarelli, Noemi; Craveiro, Licinio; Wang, Qing; Derfuss, Tobias

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

Effectiveness and Safety of Ocrelizumab in Primary and Secondary Progressive Multiple Sclerosis: Four-Year Results from the Single-Arm, Phase 3b CONSONANCE trial

McGinley, Marisa; Comi, Giancarlo; Bermel, Robert; Bar-Or, Amit; Arnold, Douglas; El Azzouzi, Bouchra; Henry, Roland; Benedict, Ralph; Bhargava, Pavan; Butzkueven, Helmut; Chard, Declan; Craveiro, Licinio; Howell, Owain; Leocani, Letizia; Lubetzki, Catherine; Montalban, Xavier; Rukina, Daria; Sormani, Maria Pia; Sellebjerg, Finn; Kazlauskaite, Agne; Lebrun-Frenay, Christine

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

Disability and Safety Outcomes of Patients With Early-Stage Relapsing Multiple Sclerosis Treated With Ocrelizumab for Up to 11 Years in the OPERA Trials

Cerqueira, Joao J.; Cree, Bruce A. C.; Filippi, Massimo; Pardo, Gabriel; Berthele, Achim; Pearson, Owen R.; Ziemssen, Tjalf; Havrdova, Eva K.; Chognot, Cathy; Schneble, Hans-Martin; Wang, Qing; Craveiro, Licinio; Traboulsee, Anthony

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

Ocrelizumab Subcutaneous Administration: Further Characterization of the Benefit-Risk Profile from the OCARINA II Study and Patient Preferences

Newsome, Scott D.; Goldstick, Lawrence; Selmaj, Krzysztof; Krzystanek, Ewa; Zecevic, Dusanka; Figueiredo, Catarina; Clinch, Susanne; Giacobino, Caroline; Azmi, Jay; Centonze, Diego

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

BAFF-APRIL System as New Potential Pharmacodynamic Biomarker for B-Cell–Targeting Therapies in Multiple Sclerosis

Bhargava, Pavan; Raposo, Catarina; Thanei, Gian-Andrea; Howell, Owain; Sellebjerg, Finn; Constantine, Florica; Ramesh, Akshaya; Craveiro, Licinio; Kazlauskaite, Agne; Bar-Or, Amit

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

A systematic literature review to evaluate published evidence on the effect of ocrelizumab extended interval dosing on clinical and safety outcomes in patients with multiple sclerosis

Joep Killestein, Elisabeth Maillart, Nicolas Lindau, Licinio Craveiro, Obaro Evuarherhe, Gary Cutter

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

B-cell Levels in Infants of Lactating Women With Multiple Sclerosis Receiving Ocrelizumab: SOPRANINO Primary Results

Hellwig, Kerstin; Oreja-Guevara, Celia; Dobson, Ruth; Vukusic, Sandra; Shah, Anna; Graham, Edith L, McElrath, Thomas F; Pietrasanta, Carlo; Kletzl, Heidemarie; Kazlauskaite, Agne; Zecevic, Dusanka; Raposo, Catarina; Craveiro, Licinio; Lin, Chien-Ju; Pasquarelli, Noemi; Bove, Riley

Neuroscience | Multiple Sclerosis

11:45 PM

Duration 45mins Florida, USA

Real-world effectiveness of first-line ocrelizumab treatment in relapsing multiple sclerosis: insights from MSBase OCR-R sub-study

Craveiro, Licinio; Butzkueven Helmut; Farr, Pamela; al Roughani, Raed; Van Der Walt, Anneke; Kalincik, Tomas; Kermode, Allan; Lechner-Scott, Jeannette; Foschi, Matteo; Boz, Cavit; Ozakbas, Serkan; Buzzard, Katherine; Skibina, Olga; Grand-Maison, Francois; Rojas, Juan; Laureys, Guy; Ramo-Tello, Cristina; Barnett, Michael; Besora, Sarah; Sotoca, Javier; Willekens, Barbara; Muros-Le Rouzic, Erwan; Spelman, Tim

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

Work, Healthcare Use, and Caregiver Burden in Patients With Low-to-moderate Disability over a 2-year Treatment with Ocrelizumab

Trojano, Maria; Van Pesch, Vincent; Cutter, Gary; al Roughani, Raed; Rovira, Alex; Camerlingo, Sebastian; Muros-Le Rouzic, Erwan; Galactionova, Katya; Craveiro, Licinio; Hobart Jeremy

Neuroscience | Multiple Sclerosis

Duration 45mins Florida, USA

Real-world adherence & persistence to ocrelizumab versus ofatumumab among pwMS over 24 months

Pineda, Elmor D.; Miller, Alexandra; Patel, Achel; Pardo, Gabriel

Neuroscience | Multiple Sclerosis

Coming soon